Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple hormone boost improve IVF success?

NCT ID NCT04806919

Disease control Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving a higher dose of vaginal progesterone (800 mg vs 1200 mg daily) can improve pregnancy rates in women with low progesterone levels on the day of embryo transfer. It involved 87 women undergoing a single frozen embryo transfer. The goal was to see if the higher dose leads to more ongoing pregnancies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
micronized progesterone (Amelgen)
What this could lead to
If successful, this could show that a higher progesterone dose helps more women achieve ongoing pregnancy after embryo transfer.
What could go wrong
This is a small, completed Phase 3 trial with only 87 participants, so results may not apply to all IVF patients. Increasing dose may not improve outcomes and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

87 people

The number who actually took part.

Started

Apr 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 43 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent form (ICF) dated and signed * Age ≥ 18 and \< 43 years old * Body Mass Index (BMI) ≥ 18.5 kg/m2 and \< 35 kg/m2 * Less than 4 previous Assisted Reproductive Technologies (ART) cycles * Current pregnancy wish * Patients undergoing a single vitrified/warmed single transfer in an artificial prepared endometrium cycle (IVF or ICSI) Exclusion Criteria: * Simultaneous participation in another clinical study * Previous participation in this study * Known reasons for impaired implantation (specifically: presence of a hydrosalpinx; presence of a type I, II or III fibroid; Asherman's syndrome; uterine malformations, intrauterine adhesions, ≥ grade 3 endometriosis according to the ASRM classification, endometrial tuberculosis) * Repeated miscarriages (\> 2 miscarriages) * Untreated and uncontrolled thyroid dysfunction * Tumors of the ovary, breast, uterus, pituitary or hypothalamus * Abnormal vaginal bleeding without a known/diagnosed cause * Ovarian cysts or enlarged ovaries * Fibroid tumors of the uterus incompatible with pregnancy * Malformations of the reproductive organs incompatible with pregnancy * Previous antibiotic hypersensitivity reactions (streptomycin and/or neomycin) * Risk factors for thromboembolic events, such as a personal or family history, severe obesity or thrombophilia * Active smoking * Ongoing pregnancy * Use of carbamazepine, rifampicin or phenytoin * Those unable to comprehend the investigational nature of the proposed study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Embryo loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Embryo Loss ventricular fibrillation, paroxysmal familial, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Embryo loss IVF Luteal phase defect

Contacts and locations

Locations

  • AZ Delta

    Roeselare, Belgium

  • UZ Ghent

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.